Cube Biotech, a portfolio company of private equity firm Archimed, announced on January 14 that it entered into an agreement to acquire IBA Lifesciences.
IBA Lifesciences is a biotechnology company providing products and custom specific services for life science applications in academia and industry worldwide. It is based in Goettingen, Germany and was founded in 1996.
Backed by Archimed since 2021, Cube Biotech is a biotechnology company based in Monheim, Germany. It is a provider of solutions for protein purification, stabilization and structural studies.
The combination of the two companies will leverage their complementary strengths to deliver solutions in protein purification and stabilization, enabling further research in the field of challenging drug targets. The financial terms were not disclosed.
“This acquisition marks an exciting new chapter for both companies,” said Didier Dargent, CEO of Cube Biotech. “Together, we will harness our collective expertise to push the boundaries of what’s possible in the life sciences and enable researchers to make groundbreaking discoveries.”
According to data in the LevinPro HC database, this marks the 12th Biotechnology transaction of 2025. Throughout 2024, there were 135 Biotechnology transactions announced. Additionally, this is the first Biotechnology transaction of 2025 where the acquirer is a private equity firm.
